Cardiome Pharma (CRME) Misses Q2 EPS by 18c

August 9, 2016 5:07 PM EDT
Get Alerts CRME Hot Sheet
Trade CRME Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Cardiome Pharma (NASDAQ: CRME) reported Q2 EPS of ($0.37), $0.18 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $5.9 million versus the consensus estimate of $6.73 million.

For earnings history and earnings-related data on Cardiome Pharma (CRME) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment